8-K: Arcturus Therapeutics Stockholders Re-Elect Board, Approve Executive Pay, and Ratify Auditor at Annual Meeting

Arcturus Therapeutics Holdings Inc. announced that its stockholders approved all proposals at the 2025 annual meeting, including the re-election of nine directors, advisory approval of executive compensation, and ratification of Deloitte & Touche LLP as independent auditors.

Summary

• Arcturus Therapeutics Holdings Inc. held its 2025 annual meeting of stockholders on June 6, 2025.
• A total of 27,120,603 shares of common stock were entitled to vote, with 22,006,524 shares present in person or by proxy, constituting a quorum for the meeting.
• Stockholders elected all nine nominated individuals to the Board of Directors: Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John H. Markels, and Dr. Moncef Slaoui. Each will serve until the 2026 annual meeting.
• The non-binding advisory resolution approving named executive officer compensation was approved with 18,472,131 votes For, 586,006 Against, and 64,724 Abstain.
• The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 21,971,168 votes For, 30,589 Against, and 4,767 Abstain.

Sentiment

Score: 7

Explanation: The document reports the successful and routine approval of all proposals at the annual stockholder meeting, indicating stable corporate governance and shareholder alignment. There are no negative surprises or significant new information, leading to a neutral to slightly positive sentiment.

Positives

• All nine director nominees were successfully re-elected to the Board of Directors, ensuring continuity in leadership.
• Stockholders approved the non-binding advisory resolution on named executive officer compensation, indicating support for the company's executive pay practices.
• The appointment of Deloitte & Touche LLP as the independent auditor for 2025 was ratified with overwhelming support.
• A strong quorum of 22,006,524 shares, representing approximately 81.14% of total eligible shares, was present at the meeting, demonstrating high shareholder engagement.

Management Comments

• Joseph E. Payne, Chief Executive Officer, signed the report on behalf of Arcturus Therapeutics Holdings Inc.

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting for a publicly traded biotechnology company, reflecting standard corporate governance practices and shareholder engagement on board composition, executive pay, and auditor oversight. Such filings are common and demonstrate compliance with regulatory requirements for public companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The successful approval of all proposals, including director elections and executive compensation, provides clarity and stability regarding the company's governance and strategic direction, reinforcing confidence in leadership and oversight.

Next Steps

• The newly elected directors will serve until the Company's 2026 annual meeting of stockholders and until their respective successors are elected and qualified.
• Deloitte & Touche LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, SEC filing, 8-K, annual meeting, stockholders, corporate governance, director election, executive compensation, auditor ratification, biotechnology, pharmaceuticals